


Extending the Spectrum of Precompetitive Oncology Biomedical Research


John A. Wagner, MD, PhD
Merck & Co., Inc.

BioPharma R&D Productivity – Declining Trends



Booth and Zimmel, Nature Reviews in Drug Discovery 3:451-6, 2004

Probability of Success for New Mechanisms ~11%



Critical Path Initiative (CPI)


§ CPI Goals

- Develop new predictive “tools”
- Improve the productivity and success of drug development
- Speed approval of innovative products

§ #1 on the list is biomarker qualification



Precompetitive Collaboration



§ “Competitors share early stages of research that benefit all”

Participant Engagement

- § The meeting is being recorded, and a workshop summary will be produced based on the transcript
- § Participant engagement is greatly encouraged,
 - If you have a question/comment, please use the microphone, and state name and affiliation for the recording
- § Interactive polling will be a new feature of this workshop—we encourage the audience to participate, but please make sure you return the polling devices at the end of the day
- § Teleconferencing and webinar options





Thanks you for coming!

**And thanks to the IOM staff !
In particular:
Erin Balogh
Michael Park**